| Literature DB >> 29581358 |
Hanae Fujimoto1,2, Yoriko Saito3, Kenoki Ohuchida4, Eiryo Kawakami5, Saera Fujiki3, Takashi Watanabe6, Rintaro Ono3, Akiko Kaneko3, Shinsuke Takagi3, Yuho Najima3, Atsushi Hijikata6, Lin Cui4, Takashi Ueki4, Yoshinao Oda7,8, Shohei Hori9, Osamu Ohara6,10, Masafumi Nakamura4, Takashi Saito2, Fumihiko Ishikawa11.
Abstract
Disturbed balance between immune surveillance and tolerance may lead to poor clinical outcomes in some malignancies. In paired analyses of adenocarcinoma and normal mucosa from 142 patients, we found a significant increase of the CD4/CD8 ratio and accumulation of regulatory T cells (Tregs) within the adenocarcinoma. The increased frequency of Tregs correlated with the local infiltration and extension of the tumor. There was concurrent maturation arrest, upregulation of programmed death-1 expression, and functional impairment in CD8+ T cells (CTLs) isolated from the adenocarcinoma. Adenocarcinoma-associated Tregs directly inhibit the function of normal human CTLs in vitro. With histopathological analysis, Foxp3+ Tregs were preferentially located in stroma. Concurrent transcriptome analysis of epithelial cells, stromal cells, and T cell subsets obtained from carcinomatous and normal intestinal samples from patients revealed a distinct gene expression signature in colorectal adenocarcinoma-associated Tregs, with overexpression of CCR1, CCR8, and TNFRSF9, whereas their ligands CCL4 and TNFSF9 were found upregulated in cancerous epithelium. Overexpression of WNT2 and CADM1, associated with carcinogenesis and metastasis, in cancer-associated stromal cells suggests that both cancer cells and stromal cells play important roles in the development and progression of colorectal cancer through the formation of a tumor microenvironment. The identification of CTL anergy by Tregs and the unique gene expression signature of human Tregs and stromal cells in colorectal cancer patients may facilitate the development of new therapeutics against malignancies.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29581358 DOI: 10.4049/jimmunol.1701222
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422